Erasca (ERAS) Times Interest Earned (2020 - 2026)
Erasca's (ERAS) quarterly Times Interest Earned came in at -$0.28 in Q1 2026, up 98.82% YoY from -$0.14 in Q1 2025, and up 98.72% on a QoQ basis from -$21.74 in Q4 2025.
Erasca (ERAS) Times Interest Earned (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Times Interest Earned data on file, last reported at -$0.28 in Q1 2026.
- Quarterly Times Interest Earned rose 98.82% year-over-year to -$0.28 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.44 (down 100.16% YoY) and the FY2025 annual result came in at -$0.58, up 95.79% from the prior year.
- Times Interest Earned climbed to -$0.28 in Q1 2026, from -$21.74 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $7.58 in Q4 2023 to a low of -$224.52 in Q4 2022.
- A 5-year average of -$17.9 and a median of -$2.09 in 2025 frame the typical range for Times Interest Earned.
- The widest YoY moves for Times Interest Earned: up 103.37% in 2023, down 678.69% in 2023.
- Tracing ERAS's Times Interest Earned over 5 years: stood at -$224.52 in 2022, then soared by 103.37% to $7.58 in 2023, then slumped by 377.29% to -$21.01 in 2024, then decreased by 3.47% to -$21.74 in 2025, then surged by 98.72% to -$0.28 in 2026.
- The last three Times Interest Earned figures came in at -$0.28 (Q1 2026), -$21.74 (Q4 2025), and -$2.09 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | -0.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.06 |
| Mar 31, 2026 | -0.28 |
| Dec 31, 2025 | -21.74 |
| Sep 30, 2025 | -2.09 |
| Jun 30, 2025 | -2.16 |
| Mar 31, 2025 | -23.75 |
| Dec 31, 2024 | -21.01 |
| Sep 30, 2024 | -2.24 |
| Jun 30, 2024 | -0.89 |
| Mar 31, 2024 | -5.16 |
| Dec 31, 2023 | 7.58 |
| Sep 30, 2023 | -1.34 |
| Jun 30, 2023 | -0.42 |
| Mar 31, 2023 | -4.23 |
| Dec 31, 2022 | -224.52 |
| Sep 30, 2022 | -0.42 |
| Jun 30, 2022 | -1.17 |
| Mar 31, 2022 | -0.54 |
| Dec 31, 2021 | -34.12 |
| Sep 30, 2021 | -0.19 |